Aqu Alu

Nov 19, 2024 | nature.com | Weiqi Hong |Aqu Alu |Zimin Chen |Hongbo Hu |Haohao Dong |Jian Lei | +8 more

AbstractThe mucosal immune response plays a crucial role in the prevention of respiratory viruses. Given the risk of recurrent SARS-CoV-2 infections in the population, the rapid development of next-generation intranasal COVID-19 vaccines with high safety and efficacy is paramount. In the current study, we developed a protein-based intranasal vaccine comprising the XBB.1.5 receptor binding domain (RBD)-derived trimeric recombinant protein (RBDXBB.1.5-HR) and an MF59-like oil-in-water adjuvant.